Helge Lubenow

We combine world-leading scientific and medical expertise with cutting-edge technical innovation, to improve diagnostic accuracy and enhance clinical care for cancer patients. The company has developed its expertise since its establishment in 2022, building on decades of combined experience of its founders. We conduct research and development, certification and marketing of software solutions for molecular tumour classification based on DNA methylation profiling and machine learning.